FRAT1

Summary

FRAT1 (FRAT regulator of Wnt signaling pathway 1, HGNC:3944) is a protein-coding gene on chromosome 10q24.1, encoding Proto-oncogene FRAT1 (Q92837). Positively regulates the Wnt signaling pathway by stabilizing beta-catenin through the association with GSK-3.

The protein encoded by this gene belongs to the GSK-3-binding protein family. The protein inhibits GSK-3-mediated phosphorylation of beta-catenin and positively regulates the Wnt signaling pathway. It may function in tumor progression and in lymphomagenesis.

Source: NCBI Gene 10023 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 49 total
• MANE Select transcript: NM_005479

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3944
Approved symbol	FRAT1
Name	FRAT regulator of Wnt signaling pathway 1
Location	10q24.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000165879
Ensembl biotype	protein_coding
OMIM	602503
Entrez	10023

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000371021, ENST00000490980

RefSeq mRNA: 1 — MANE Select: NM_005479 NM_005479

CCDS: CCDS7455

Canonical transcript exons

ENST00000371021 — 1 exons

Exon	Start	End
ENSE00001454138	97319271	97321915

Expression profiles

Bgee: expression breadth ubiquitous, 217 present calls, max score 92.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.6294 / max 208.2473, expressed in 1235 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106424	2.6626	853
106425	1.9668	705

Top tissues by expression

264 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	92.49	gold quality
monocyte	CL:0000576	91.48	gold quality
mononuclear cell	CL:0000842	91.18	gold quality
leukocyte	CL:0000738	91.13	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.66	gold quality
granulocyte	CL:0000094	87.10	gold quality
pancreatic ductal cell	CL:0002079	85.97	gold quality
secondary oocyte	CL:0000655	84.50	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.84	gold quality
oocyte	CL:0000023	82.14	gold quality
right lobe of liver	UBERON:0001114	80.27	gold quality
bone marrow	UBERON:0002371	79.25	gold quality
spleen	UBERON:0002106	79.16	gold quality
mucosa of transverse colon	UBERON:0004991	77.61	gold quality
palpebral conjunctiva	UBERON:0001812	77.36	gold quality
bone marrow cell	CL:0002092	77.23	gold quality
apex of heart	UBERON:0002098	75.67	gold quality
right testis	UBERON:0004534	75.54	gold quality
left testis	UBERON:0004533	75.22	gold quality
liver	UBERON:0002107	74.11	gold quality
endothelial cell	CL:0000115	73.50	silver quality
testis	UBERON:0000473	72.96	gold quality
hindlimb stylopod muscle	UBERON:0004252	72.88	gold quality
stromal cell of endometrium	CL:0002255	72.70	gold quality
vermiform appendix	UBERON:0001154	71.96	gold quality
trabecular bone tissue	UBERON:0002483	71.58	gold quality
duodenum	UBERON:0002114	71.48	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	71.37	gold quality
right lung	UBERON:0002167	71.33	gold quality
body of stomach	UBERON:0001161	70.62	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.03

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

64 targeting FRAT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-4690-5P	99.65	66.24	813
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084

Literature-anchored findings (GeneRIF, showing 18)

• CKI epsilon-dependent phosphorylation of Dvl enhances the formation of a complex of Dvl-1 with Frat-1 and this complex leads to the activation of Wnt-3a-induced accumulation of beta-catenin (PMID:12556519)
• findings support that Wnt/beta-catenin signalling may be aberrantly activated through FRAT1 overexpression in ovarian serous adenocarcinomas (PMID:16479254)
• PKA phosphorylates FRAT1 in vitro as well as in intact cells and may play a role in regulating the inhibitory activity of FRAT1 toward GSK-3. (PMID:16982607)
• Aberrant activation of beta-catenin/TCF pathway in esophageal cancer appears to be due to upstream events such as FRAT1 overexpression, and c-Myc may be an important element in oncogenesis of human ESCC induced by FRAT1. (PMID:18498136)
• Elevated expression of FRAT1 was associated with astrocytomas. (PMID:20041315)
• Our results suggest that FRAT1 may be an important factor in the tumorigenesis and progression of gliomas, and could be used as a potential molecular marker for pathological diagnosis and a target for biological therapy. (PMID:20096670)
• Down-regulation of Frat1 expression reduced invasive ability in A549 cell line, further supporting idea that Frat1 may play crucial role in carcinogenesis, tumor invasiveness and dissemination in human lung cancer. (PMID:21818639)
• The overexpression of Frat1 and beta-catenin was correlated with tumor differentiation, TNM stage, lymph node metastasis, and poor prognosis of NSCLC. (PMID:22528942)
• These results highlight the potential role of FRAT1 in tumorigenesis and progression of glioblastoma. (PMID:23613813)
• The mechanism of inhibiting beta-catenin phosphorylation involves the NDRG1-mediated upregulation of the GSK3beta-binding protein FRAT1. (PMID:24829151)
• Positive ROR2 and FRAT1 expression is associated with the progression and poor prognosis of chondrosarcoma. (PMID:25387569)
• FRAT1 overexpression correlates with pathologic grade, proliferation, invasion and angiogenesis in brain gliomas. (PMID:25922553)
• FRAT1 and ABCG2 overexpression is associated with carcinogenesis, progression, and poor prognosis in patients with Pancreatic ductal adenocarcinoma. (PMID:26178481)
• The results of the present study suggest that nuclear FRAT1 activates the Wnt/beta-catenin signaling pathway and confers an increase in prostate cancer cell growth. (PMID:27599661)
• These data suggest a potential role for targeting FRAT1 in the prevention of hypoxia-induced HCC cancer progression and metastasis mediated by epithelial-to-mesenchymal transition (PMID:27666874)
• LncRNA CCAT1 promotes prostate cancer cells proliferation, migration, and invasion through regulation of miR-490-3p/FRAT1 axis. (PMID:34319909)
• FRAT1 promotes the angiogenic properties of human glioblastoma cells via VEGFA. (PMID:35059733)
• The miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop modulates the metastasis and invasion of gastric cancer cells. (PMID:36153370)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Frat1	ENSMUSG00000067199
mus_musculus	Peg12	ENSMUSG00000070526
rattus_norvegicus	Peg12	ENSRNOG00000024429
rattus_norvegicus	Frat1	ENSRNOG00000067076

Paralogs (1): FRAT2 (ENSG00000181274)

Protein

Protein identifiers

Proto-oncogene FRAT1 — Q92837 (reviewed: Q92837)

Alternative names: Frequently rearranged in advanced T-cell lymphomas 1

All UniProt accessions (1): Q92837

UniProt curated annotations — full annotation on UniProt →

Function. Positively regulates the Wnt signaling pathway by stabilizing beta-catenin through the association with GSK-3. May play a role in tumor progression and collaborate with PIM1 and MYC in lymphomagenesis.

Subunit / interactions. Binds DVL1. Binds GSK-3 and prevent GSK-3-dependent phosphorylation.

Subcellular location. Cytoplasm.

Post-translational modifications. Phosphorylated.

Similarity. Belongs to the GSK-3-binding protein family.

RefSeq proteins (1): NP_005470* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008014	GSK3-bd	Family

Pfam: PF05350

UniProt features (14 total): region of interest 5, modified residue 3, sequence conflict 2, helix 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
4AFJ	X-RAY DIFFRACTION	1.98
3ZRK	X-RAY DIFFRACTION	2.37
3ZRL	X-RAY DIFFRACTION	2.48
3ZRM	X-RAY DIFFRACTION	2.49
1GNG	X-RAY DIFFRACTION	2.6
5OY4	X-RAY DIFFRACTION	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92837-F1	60.81	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 88, 249, 252

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-196299	Beta-catenin phosphorylation cascade
R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane

MSigDB gene sets: 237 (showing top): BENPORATH_ES_WITH_H3K27ME3, YANG_BREAST_CANCER_ESR1_LASER_UP, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_REGULATION_OF_PROTEIN_EXPORT_FROM_NUCLEUS, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GOBP_NUCLEAR_TRANSPORT, GOBP_REGULATION_OF_NUCLEOCYTOPLASMIC_TRANSPORT, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, BILD_E2F3_ONCOGENIC_SIGNATURE, GOBP_REGULATION_OF_INTRACELLULAR_PROTEIN_TRANSPORT, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, GNF2_HCK, TCCAGAT_MIR5165P

GO Biological Process (4): regulation of protein export from nucleus (GO:0046825), canonical Wnt signaling pathway (GO:0060070), positive regulation of canonical Wnt signaling pathway (GO:0090263), Wnt signaling pathway (GO:0016055)

GO Molecular Function (2): molecular function inhibitor activity (GO:0140678), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Degradation of beta-catenin by the destruction complex	1
TCF dependent signaling in response to WNT	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein export from nucleus	1
regulation of intracellular protein transport	1
regulation of nucleocytoplasmic transport	1
Wnt signaling pathway	1
positive regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
cell surface receptor signaling pathway	1
molecular function regulator activity	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

576 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FRAT1	AXIN1	O15169	984
FRAT1	GSK3B	P49841	979
FRAT1	DVL1	O14640	954
FRAT1	RHOA	P06749	769
FRAT1	CTNNB1	P35222	697
FRAT1	MAP3K4	Q9Y6R4	695
FRAT1	LRP6	O75581	525
FRAT1	GSK3A	P49840	477
FRAT1	GYS1	P13807	471
FRAT1	EPM2A	O95278	436
FRAT1	WNT1	P04628	433
FRAT1	NHLRC1	Q6VVB1	430
FRAT1	LRP5	O75197	426
FRAT1	MAPK6	Q16659	425
FRAT1	CD244	Q9BZW8	410

IntAct

28 interactions, top by confidence:

A	B	Type	Score
AXIN1	GSK3B	psi-mi:“MI:0217”(phosphorylation reaction)	0.980
GSK3B	AXIN1	psi-mi:“MI:0914”(association)	0.980
FRAT1	GSK3B	psi-mi:“MI:0407”(direct interaction)	0.810
GSK3A	AXIN1	psi-mi:“MI:0914”(association)	0.800
FRAT1	GSK3A	psi-mi:“MI:0915”(physical association)	0.740
Ctnnb1	GSK3B	psi-mi:“MI:0217”(phosphorylation reaction)	0.620
AXIN1	GSK3B	psi-mi:“MI:0914”(association)	0.520
AXIN1		psi-mi:“MI:0914”(association)	0.520
FRAT1		psi-mi:“MI:0407”(direct interaction)	0.440
FRAT1	GSK3B	psi-mi:“MI:0407”(direct interaction)	0.440
EIF2B5	GSK3B	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
GSK3B	SEC16A	psi-mi:“MI:0914”(association)	0.420
GRN	FRAT1	psi-mi:“MI:0915”(physical association)	0.370
KRT18	FRAT1	psi-mi:“MI:0915”(physical association)	0.370
PLSCR1	FRAT1	psi-mi:“MI:0915”(physical association)	0.370
PSMA3	FRAT1	psi-mi:“MI:0915”(physical association)	0.370
FRAT1	LTBP4	psi-mi:“MI:0915”(physical association)	0.370
KCNK5	FRAT1	psi-mi:“MI:0915”(physical association)	0.370
FRAT1	LAMC3	psi-mi:“MI:0915”(physical association)	0.370
FRAT1	LMAN2	psi-mi:“MI:0915”(physical association)	0.370
FRAT1	TDRD7	psi-mi:“MI:0915”(physical association)	0.370
RABEP2	FRAT1	psi-mi:“MI:0915”(physical association)	0.370
GPRASP2	FRAT1	psi-mi:“MI:0915”(physical association)	0.370
FRAT1	PIAS1	psi-mi:“MI:0914”(association)	0.350

BioGRID (24): FRAT1 (Affinity Capture-Western), FRAT1 (Affinity Capture-Luminescence), GSK3A (Affinity Capture-MS), GSK3B (Affinity Capture-MS), KRAS (Affinity Capture-MS), PIAS1 (Affinity Capture-MS), FRAT1 (Affinity Capture-MS), DVL1 (Affinity Capture-Western), FRAT1 (Affinity Capture-MS), FRAT1 (Protein-peptide), GPRASP2 (Two-hybrid), LAMC3 (Two-hybrid), KRT18 (Two-hybrid), GRN (Two-hybrid), PLSCR1 (Two-hybrid)

ESM2 similar proteins: A0A0U1RRK4, A0A1W2PPE3, A0A1W2PR82, A0A2Z4LIS9, A2VE02, A4D1S0, A5PKC7, A5PL33, A6H7B4, A6NEL2, A6QP24, A6QPM6, A8MTW9, A8MYA2, D3ZAQ5, D4AAA5, E7EW31, O75474, O75638, O89113, O94850, P0C7X2, P14652, P50617, P70339, Q2KIS6, Q3UN58, Q5JPB2, Q5VZ46, Q6GQX2, Q6NZ36, Q6ZSJ8, Q6ZW13, Q76NI1, Q7TNS8, Q80TS7, Q86UU5, Q8IWN7, Q8N6K4, Q8N944

Diamond homologs: O75474, O93343, P70339, Q8K025, Q92837

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
PRKACA	down-regulates	FRAT1	phosphorylation
FRAT1	up-regulates	GSK3B/Axin/APC	binding
GSK3B	“down-regulates activity”	FRAT1	phosphorylation
PKA	“down-regulates activity”	FRAT1	phosphorylation
FRAT1	up-regulates	GSK3B	binding
DVL3	up-regulates	FRAT1	binding
FRAT1	“up-regulates activity”	EIF2B5	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

49 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	48
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

120 predictions. Top by Δscore:

Variant	Effect	Δscore
10:97320132:T:G	donor_gain	0.8800
10:97319481:G:GT	donor_gain	0.8100
10:97319475:G:GT	donor_gain	0.7900
10:97321024:TAAAG:T	acceptor_gain	0.7700
10:97320692:T:G	donor_gain	0.7300
10:97321683:A:AG	acceptor_gain	0.7100
10:97321684:G:GG	acceptor_gain	0.7100
10:97319540:GCA:G	donor_gain	0.6700
10:97319493:G:GT	donor_gain	0.6500
10:97319508:G:GT	donor_gain	0.6500
10:97319514:G:GT	donor_gain	0.6400
10:97320137:TGCA:T	donor_gain	0.6400
10:97319542:A:AG	donor_gain	0.6300
10:97319543:G:GG	donor_gain	0.6300
10:97319438:GCCC:G	donor_gain	0.6000
10:97320096:G:GT	donor_gain	0.5900
10:97321025:AAAG:A	acceptor_gain	0.5900
10:97319517:G:GT	donor_gain	0.5700
10:97320422:G:GT	donor_gain	0.5600
10:97320681:G:GT	donor_gain	0.5600
10:97320436:C:T	donor_gain	0.5500
10:97321684:GTCA:G	acceptor_gain	0.5500
10:97319472:G:GT	donor_gain	0.5400
10:97320394:G:GT	donor_gain	0.5400
10:97319572:T:TA	donor_gain	0.5300
10:97319573:G:GA	donor_gain	0.5300
10:97321685:T:G	acceptor_gain	0.5300
10:97319613:G:GT	donor_gain	0.5200
10:97319545:C:A	donor_gain	0.5100
10:97320335:C:T	donor_gain	0.4900

AlphaMissense

1721 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:97320095:G:C	K214N	0.996
10:97320095:G:T	K214N	0.996
10:97320082:G:T	G210V	0.995
10:97320091:T:A	I213N	0.995
10:97320091:T:C	I213T	0.995
10:97320091:T:G	I213S	0.993
10:97320082:G:A	G210E	0.991
10:97320099:G:C	A216P	0.991
10:97320088:T:C	L212P	0.987
10:97320070:T:C	L206P	0.986
10:97320088:T:A	L212H	0.984
10:97320094:A:T	K214M	0.984
10:97320081:G:A	G210R	0.982
10:97320081:G:C	G210R	0.982
10:97319593:T:G	I47S	0.980
10:97320086:C:A	N211K	0.980
10:97320086:C:G	N211K	0.980
10:97320100:C:A	A216D	0.979
10:97319593:T:A	I47N	0.978
10:97320096:G:A	E215K	0.972
10:97319581:T:C	L43P	0.969
10:97320093:A:G	K214E	0.967
10:97320097:A:T	E215V	0.967
10:97320110:G:C	R219S	0.967
10:97320110:G:T	R219S	0.967
10:97320085:A:T	N211I	0.966
10:97320079:C:T	S209F	0.964
10:97320097:A:G	E215G	0.961
10:97320094:A:C	K214T	0.960
10:97319593:T:C	I47T	0.959

dbSNP variants (sampled 300 via entrez): RS1000145657 (10:97321957 T>C), RS1000157063 (10:97321646 A>G), RS1001935435 (10:97320796 C>A), RS1002458847 (10:97317679 C>T), RS1002617535 (10:97317936 T>C), RS1003040469 (10:97322189 T>G), RS1003331162 (10:97321837 T>C), RS1003491854 (10:97319061 C>T), RS1004233060 (10:97319216 G>A,C), RS1004578398 (10:97319055 C>A), RS1005238635 (10:97319091 G>A), RS1006343498 (10:97321464 C>G,T), RS1006374489 (10:97321760 T>G), RS1006496072 (10:97317707 C>A,G), RS1007054172 (10:97321530 G>T)

Disease associations

OMIM: gene MIM:602503 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST90002388_572	Lymphocyte count	2.000000e-12
GCST90002407_310	White blood cell count	2.000000e-77
GCST90013405_22	Liver enzyme levels (alanine transaminase)	3.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004587	lymphocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	decreases expression	3
Estradiol	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Valproic Acid	decreases expression, increases expression	2
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	decreases expression	1
afimoxifene	decreases reaction, decreases expression	1
butyraldehyde	decreases expression	1
ochratoxin A	decreases expression	1
ferrous chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects response to substance	1
pentanal	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
PKF115-584	increases expression	1
jinfukang	increases expression, affects cotreatment	1
NSC 689534	affects binding, decreases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	decreases expression	1
Aldehydes	decreases expression	1
Atrazine	decreases expression	1
Hexachlorocyclohexane	increases expression	1
Benzo(a)pyrene	decreases expression	1
Carbamazepine	affects expression	1
Cisplatin	affects cotreatment, increases expression	1
Copper	affects binding, decreases expression	1
Environmental Pollutants	affects expression	1
Estrogens	decreases expression, decreases reaction	1

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9F2	Ubigene HEK293 FRAT1 KO	Transformed cell line	Female
CVCL_E0DA	Ubigene HeLa FRAT1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.